Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels(UCLouvain), Ezra E.W. Cohen(Moores Cancer Center), Jan B. Vermorken(University of Antwerp), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), Jérôme Fayette(Université Claude Bernard Lyon 1), Thomas Gauler, Lisa Licitra(University of Milan), Luciano de Souza Viana(Hospital de Câncer de Barretos), Ulrich Keilholz(German Cancer Research Center), Robert I. Haddad(Georgetown University), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Francesco Caponigro, Joseph M del Campo(Vall d'Hebron Hospital Universitari), Paul M. Clément(Universitair Ziekenhuis Leuven), Juan J. Grau(Hospital Clínic de Barcelona), Xiuyu Julie Cong(Boehringer Ingelheim (United States))
The Lancet Oncology
April 17, 2015
10.1016/s1470-2045(15)70124-5
Cited by 394

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k